Home Page >> Settlements >> J&J Agrees to Pay $85 Million for Natrecor Misbranding

J&J Agrees to Pay $85 Million for Natrecor Misbranding

Washington, DC: Johnson & Johnson subsidiary, Scios, has agreed to pay $85 million to settle a criminal misdemeanour charge of misbranding its drug Natrecor, used to treat heart failure.

The charges stemmed from a Justice Department probe into allegations brought by a whistleblower that Scios was promoting Natrecor for off-label use as a routine, outpatient infusion, when it is only FDA approved for use to treat congestive heart failure patients in hospitals and emergency rooms. The settlement doesn't exempt Scios or J&J from separate civil claims in a pending False Claims Act suit.

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.

Last updated on Oct-11-11